[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alcohol-related-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alcohol-related-liver-disease":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,72,98,128,159,179,198],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100623512","peer-support-for-liver-transplant-recipients-with-history-of-ald-100623512",false,"NCT07397598","Peer Support for Liver Transplant Recipients With History of ALD","Peer Support to Enhance Care for Liver Transplant Recipients Who Had Alcohol-Associated Liver Disease","THRIVE","Inclusion Criteria:\n\n* English speakers\n* Received a liver transplant for alcohol-associated liver disease\n* Has 1 to 3 years of continuous alcohol abstinence at the time of trial entry\n\nExclusion Criteria:\n\n* Liver transplant recipients without a history of alcohol-associated liver disease\n* Inability to provide informed consent\n* Active participation in a separate intervention trial for alcohol use disorder","ALL","18 Years",{"count":20,"type":21},95,"ESTIMATED","INTERVENTIONAL",[24],"NA","Liver transplant (LT) recipients with a history of alcohol-related liver disease (ALD) may encounter various psychosocial and medical challenges during post-LT recovery, even beyond the initial post-transplant period. Effective and sustainable interventions will be crucial for improving patient outcomes. This clinical trial will examine the impact of peer support specialists (PSS) on the recovery experience of individuals who received LT for ALD. The trial seeks to answer two main questions:\n\n* Are LT recipients who work with PSS less likely to resume alcohol use or tend to drink less overall?\n* Do LT recipients who work with PSS engage more with recommended medical care and have better overall survival?",[27,28,29],"Alcohol Use Disorder","Alcohol Related Liver Disease","Liver Transplant Recipient",[31,28,32,33],"Alcohol use disorder","Liver transplant recipient","Peer support specialist","NOT_YET_RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2029-06",{"name":44,"class":45},"Johns Hopkins University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100539575","implementation-of-mobile-based-programs-for-alcohol-cessation-in-treatment-of-alcohol-associated-liver-disease-100539575","NCT06305624","Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease","Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease (IMPACT-ALD): Aim 1","IMPACT-ALD","Inclusion Criteria:\n\n* Diagnosis of ALD (any stage)\n* Alcoholic liver disease (ALD) encompasses a spectrum of hepatic injuries caused by long-term alcohol abuse. For this study, participants will have a diagnosis of ALD or evidence of the combination of liver disease and alcohol misuse in electronic health record.\n* Alcohol use within the last 6 months\n* Receiving care at UW or Henry Ford Health + MSU\n\n  * Either the general hepatology clinic or the multidisciplinary ALD clinic\n* Able to read and write proficiently in English\n* Willing and able to use a smartphone app\n\nExclusion Criteria:\n\n* Actively listed for liver transplant or history of liver transplant before being enrolled in the study. Participants added to a liver transplant list after being enrolled in the study will be allowed to continue their participation\n* In hospice care\n* Has severe cognitive impairment (as described in electronic health record including dementia, delirium, and\u002For unable to maintain cognitive alertness during screening--as determined by study staff.)",{"count":56,"type":21},298,[24],"This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical centers in Michigan and Wisconsin, in two types of clinics: general hepatology and multidisciplinary that offers care for advanced ALD alongside co-located, integrated mental health and substance abuse treatment. The long-term goal of this and future work is to prevent disease progression and promote healthy behaviors by improving the rate of abstinence among patients with ALD earlier in the course of their disease. 298 participants will be enrolled and can expect to be on study for up to 6 months.",[27,60],"Alcohol-related Liver Disease","RECRUITING","2026-04-13",{"date":64,"type":38},"2026-04-14",{"date":66,"type":38},"2024-06-01",{"date":68,"type":21},"2027-10-31",{"name":70,"class":45},"University of Wisconsin, Madison",3,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100487136","chronic-hepatopathies-associated-with-alcohol-consumption-and-metabolic-syndrome-100487136","NCT05623150","CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome","CHALNA2","Inclusion Criteria:\n\n* Criteria common to all patients:\n\n  1. Affiliation to French social security.\n  2. Male or female ≥ 18 years of age\n  3. Patients able to receive and understand information about the research and to give written informed consent duly signed by the patient and the investigator (at the latest on the day of inclusion and before any examination necessary for the research).\n* Patients in the NAFLD group with HCC:\n\n  1. Alcohol consumption ≤ 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and ≤ 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) for women.\n  2. Decision, less than 3 months old, of liver biopsy of the suspected HCC nodule and non-tumour liver tissue performed as a clinical routine.\n  3. No systemic treatment for HCC within 6 months prior to inclusion.\n* Patients in the NAFLD group without HCC:\n\n  1. Alcohol consumption ≤ 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and ≤ 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) for women.\n  2. Decision of less than 3 months of a liver biopsy performed as a clinical routine. Biopsy will be motivated by liver function disturbance(s) and\u002For ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and\u002For fibrosis in some of these patients.\n* Patients in the alcohol-related liver disease group with HCC:\n\n  1. Alcohol consumption \\> 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and \\> 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) or binge drinking\n  2. Decision within 3 months of liver biopsy of suspected HCC nodule and non-tumour liver tissue performed as part of clinical routine\n  3. No systemic treatment for HCC within 6 months prior to inclusion.\n* Patients in the alcohol-related liver disease group without HCC:\n\n  1. Alcohol consumption \\> 30 g pure alcohol\u002Fd (or 210 g pure alcohol\u002Fweek) for men and \\> 20 g pure alcohol\u002Fd (140 g pure alcohol\u002Fweek) or binge drinking\n  2. Decision of less than 3 months for a liver biopsy to be performed as a clinical routine. Biopsy will be motivated by liver balance disturbance(s) and\u002For ultrasound steatosis given the lack of validated non-invasive tests or the lack of accuracy (grey areas) of available non-invasive tests for the diagnosis of necro-inflammation and\u002For fibrosis in some of these patients.\n\nExclusion Criteria:\n\n1. Positive HIV serology\n2. Patients with detectable hepatitis C viral load\n3. Presence of Hbs antigen\n4. History of autoimmune hepatitis type 1 or 2, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, genetic haemochromatosis homozygous, alpha1 anti-trypsin deficiency\n5. Long-term use of methotrexate, corticosteroids, anti-Tumor Necrosis Factor cyclosporine, tacrolimus\n6. History of solid organ transplantation or bone marrow transplantation\n7. Cancerous disease in the process of being treated, except for skin cancer (excluding melanoma)\n8. Patients under legal protection or unable to express their consent,\n9. Pregnant or breastfeeding women",{"count":80,"type":21},710,"OBSERVATIONAL","The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic steatosis\u002FNon-Alcoholic SteatoHepatitis.\n\nThe investigators will include patients with and without cirrhosis in order to identify early molecular mechanisms involved in the development of HCC especially in non-cirrhotic patients.",[84,85,60,86,87],"Non-Alcoholic Fatty Liver Disease","Non-Alcoholic Steatohepatitis","Cirrhosis, Liver","Hepatocellular Carcinoma",[84,85,60,86,87],{"date":90,"type":38},"2026-04-16",{"date":92,"type":38},"2022-12-06",{"date":94,"type":21},"2032-03",{"name":96,"class":97},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100536798","enhancing-alcohol-treatment-engagement-in-associated-liver-disease-ald-patients-100536798","NCT06269510","Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients","Enhancing Alcohol Treatment Engagement in ALD Patients","ENGAGE-ALD","Inclusion Criteria:\n\n* Willingness to comply with all study procedures and availability for the duration of the study\n* Willing and able to provide informed consent\n* Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals\n* Documented diagnosis of alcohol-related liver disease (ALD) (per protocol)\n* Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record.\n* No alcohol use treatment within the past 1 month including, but not limited to:\n\n  * Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use.\n  * Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery)\n  * Community-based church support groups primarily focused on alcohol abstinence or reduction in use.\n  * Residential (inpatient) alcohol treatment\n  * Intensive outpatient programs\n  * Any telehealth version of the above options\n* Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling\u002Fdata plan at no cost to subject by the study team for the duration of the research stud.\n* Ability to speak and comprehend English\n\nExclusion Criteria:\n\n* Unable to provide voluntary informed consent for any reason\n* Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score \\>=10 on the Short Blessed Test for cognitive impairment.\n* Unable to read or understand English\n* Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation\n* Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine\n* Any other medical condition or circumstance that precludes safe and meaningful participation in the study\n* History of nonadherence to previous clinical or research studies",{"count":107,"type":21},268,[24],"The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.",[60,111],"Liver Diseases",[113,114,115,116,117,118],"Online web application","Engagement","Alcohol use disorder (AUD) treatment","Alcohol-related cirrhosis","SMART trial","Behavioral treatment","2026-01-30",{"date":121,"type":38},"2026-02-03",{"date":123,"type":38},"2026-01-28",{"date":125,"type":21},"2030-02",{"name":127,"class":45},"Henry Ford Health System",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":139,"conditions":140,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100599634","a-study-to-predict-recompensation-in-patients-with-decompensated-cirrhosis-using-spleen-stiffness-and-simple-blood-tests-100599634","NCT07087041","A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests","Prediction of Recompensation and Stable Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness Combined With Non-Invasive Markers: A Prospective, Observational, Multicenter Study","LEAD-2","Inclusion Criteria:\n\n* Male or female, aged 18 to 75 years (inclusive)\n* Clinically diagnosed decompensated cirrhosis\n* First decompensated event occurred within 12 months of screening, or no decompensated events in the past 12 months despite a history of decompensation\n* Received effective etiological treatment per guidelines:\n\n  * For HBV: Sustained antiviral suppression\n  * For alcohol-related liver disease: Sustained abstinence for ≥2 months\n  * For MAFLD-related cirrhosis: Improved liver function after lifestyle\u002F metabolic intervention\n\nExclusion Criteria:\n\n* Missing data on first decompensated event\n* Prior orthotopic liver transplantation or TIPS\n* Prior splenectomy, splenic embolization, or other shunt surgery\n* History or current diagnosis of hepatocellular carcinoma\n* Acute variceal bleeding within the last 4 weeks or unstable condition\n* Uncontrolled moderate-to-severe ascites\n* Cholestatic cirrhosis; untreated chronic liver diseases; non-cirrhotic portal hypertension; vascular liver diseases (e.g., Budd-Chiari syndrome)\n* Acute or chronic portal vein thrombosis\n* Severe comorbidities of heart, lung, kidney, brain, hematologic, or psychiatric systems\n* Other systemic malignancies (except cured cases)\n* Pregnant or breastfeeding women","75 Years",{"count":138,"type":21},735,"The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of their liver disease. The main questions it aims to answer are:\n\n* Can spleen stiffness and blood test results predict who will get better and stay better after cirrhosis becomes worse?\n* What are the features of people who recover after decompensation?\n\nParticipants will:\n\n* Be people with decompensated cirrhosis who are already getting effective treatment (such as antiviral therapy or alcohol abstinence)\n* Be followed over time to check if they remain stable or have more liver problems\n* Have non-invasive tests done, including spleen stiffness measurement and blood tests\n\nResearchers will track how many participants recover and stay recovered over time, and use that information to build a tool to help predict outcomes in others with cirrhosis.",[141,142,143,144,145,146],"Decompensated Cirrhosis","Hepatitis B Virus (HBV) Infection","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Alcohol-Related Liver Disease","Portal Hypertension","Recompensation",[146,141,148],"Spleen Stiffness","2025-07-23",{"date":151,"type":38},"2025-07-25",{"date":153,"type":21},"2025-07-15",{"date":155,"type":21},"2028-12-30",{"name":157,"class":45},"Beijing Friendship Hospital",28,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":46},"100597596","investigating-hepquant-duo-test-as-a-biomarker-in-alcohol-related-liver-disease-100597596","NCT07060547","Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease","Inclusion Criteria:\n\n* adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.\n\nadult with a combined clinical diagnosis of alcohol-related liver disease (ALD) and nonalcoholic steatohepatitis (NASH).\n\nExclusion Criteria:\n\n* Clinical diagnosis of liver disease with an etiology other than alcohol liver disease unless it is a combined clinical diagnosis of ALD and NASH.\n* patients with solid organ malignancy.\n* patients with other disease affecting the liver including autoimmune, drug-related liver injury, hemochromatosis or Wilson's disease\n* pregnancy\n* under the age of 18",{"count":166,"type":21},40,"This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.",[169,60],"Alcoholic Hepatitis","2025-07-01",{"date":172,"type":38},"2025-07-11",{"date":174,"type":38},"2025-06-10",{"date":94,"type":21},{"name":177,"class":178},"HepQuant, LLC","INDUSTRY",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":46},"100574739","genetic-polymorphisms-associated-with-the-risk-of-pancreatitis-in-patients-with-alcohol-related-cirrhosis-100574739","NCT06763198","Genetic Polymorphisms Associated With the Risk of Pancreatitis in Patients With Alcohol Related Cirrhosis.","Inclusion Criteria:\n\n1. Patients \\> 18 years of age.\n2. Alcohol-related cirrhosis\n3. Males\n\nExclusion Criteria:\n\n1. Current Hepatic encephalopathy or cognitive dysfunction precluding adequate nutritional and functional assessment.\n2. HCC.\n3. Complete or partial PVT.\n4. Significant cardio-pulmonary comorbidity\n5. Patients who do not consent for genetic study\n6. Inability to provide informed consent.\n7. Cannot understand Hindi or English should be excluded since they will not be able to reply objectively to questionnaire.",{"count":186,"type":21},150,"Alcohol is a known risk factor for both pancreatitis and cirrhosis. However, not all patients with alcohol related cirrhosis develop pancreatitis. It is not known which patients with alcohol-related cirrhosis develop symptomatic or clinically inapparent pancreatitis (Acute or Chronic Pancreatitis).There is no data whether genetic polymorphisms predispose patients with alcohol-related cirrhosis to additional pancreatic injury. There is no data on the spectrum of clinical and subclinical pancreatic changes (structural and functional) in patients with alcohol-related cirrhosis, and their genotypic correlates.This study aims to determine pancreatitis-related gene variants among patients with alcohol-related cirrhosis, with and without pancreatitis. We also aim to study differences in nutritional and functional parameters among alcoholic cirrhosis with and without chronic pancreatitis and also define the relationship of genetic polymorphisms with the pancreatic phenotype. Consecutive patients with alcohol related cirrhosis will be screened for changes of pancreatitis on CT\u002FMR\u002FEUS. Those with and without pancreatitis will be compared with respect to demographic, clinical, genotype, nutritional status .We will also be including a group of MAFLD\u002FCryptogenic cirrhosis for genotypic and phenotypic comparison.",[60],"2025-01-20",{"date":191,"type":38},"2025-01-22",{"date":193,"type":21},"2025-01-25",{"date":195,"type":21},"2026-01-31",{"name":197,"class":45},"Institute of Liver and Biliary Sciences, India",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":46},"100573723","risk-and-protective-factors-for-relapse-to-alcohol-use-in-patients-with-liver-disease-undergoing-liver-transplantation-100573723","NCT06749990","Risk and Protective Factors for Relapse to Alcohol Use in Patients With Liver Disease Undergoing Liver Transplantation","Risk and Protective Factors for Relapse to Alcohol Use in Patients With Alcohol-related Liver Disease and Undergoing Orthotopic Liver Transplantation","Inclusion Criteria:\n\n* Patients who have signed the informed consent\n* Candidates for liver transplantation due to liver disease with alcohol-related etiology (either mono- or multifactorial)\n* For the retrospective part: patients who underwent OLT for ARLD during the time frame 2017-2022\n\nExclusion Criteria:\n\n* Major psychopathologies and active psychoses",{"count":206,"type":21},320,"This is an observational, monocentric study, consisting of both a retrospective and a prospective component. The aim of the study is to identify risk and protective factors for alcohol relapse in patients with alcohol-related liver disease (ARLD) who have undergone orthotopic liver transplantation (OLT).",[28,209],"Orthotopic Liver Transplantation","2024-12-19",{"date":212,"type":38},"2024-12-27",{"date":214,"type":38},"2024-01-09",{"date":216,"type":21},"2030-12-31",{"name":218,"class":45},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]